China Salt Substitute and Stroke Study

Overview

The study is a large scale cluster randomised trial to evaluate the effects of sodium reduction based upon the use of salt substitute on the risk of stroke defined as the occurrence of stroke and stroke deaths. The corresponding null hypothesis that will be tested is that sodium reduction will have no effect upon stroke risk. The secondary objectives are to determine effects of sodium reduction on major vascular events and total mortality.

Full Title of Study: “A LARGE-SCALE CLUSTER RANDOMIZED TRIAL TO DETERMINE THE EFFECTS OF SODIUM REDUCTION ON STROKE: THE CHINA SALT SUBSTITUTE AND STROKE STUDY (SSaSS)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Double (Investigator, Outcomes Assessor)
  • Study Primary Completion Date: September 4, 2020

Detailed Description

Lowering sodium intake and the use of salt substitute have been proved to lower blood pressure levels. Effects on the risks of vascular outcomes have not been defined in an adequately powered randomised trial. Rural Chinese are known to consume very large quantities of sodium and to suffer from very high rates of hypertension and stroke. This study is a large scale cluster randomised trial done in rural areas of China. The study will define the effects of a salt substitute-based sodium reduction strategy on the primary outcome of stroke. Secondary endpoints will include major cardiovascular events and total mortality. The study will be conducted in 600 rural villages across five Northern Chinese provinces and Tibet. The study will recruit 35 individuals at elevated risk of stroke from each village for a total of 21,000 participants. The participating villages will be randomised into intervention and control group with 1:1 allocation. Recruitment will prioritise individuals with a history of stroke but also include older individuals with high blood pressure. Follow up is scheduled for 5 years. Individuals in intervention villages will receive repeated dietary advice and a supply of low sodium salt substitute while individuals in control villages will receive dietary advice at baseline only. Every 6 months throughout follow-up each individual will be contacted by phone call to inquire about the occurrence of stroke, hospitalisation for any cause and diagnoses of any other serious illnesses. The interview will be structured and done by individuals masked to the randomised assignment of each individual. For all deaths identified and all events that might possibly be non-fatal strokes a home visit will be made. A series of process indicators including urinary sodium, urinary potassium, blood pressure, knowledge about sodium and use of salt substitute will also be measured on a random sample of at least 20 individuals drawn from a random selection of 60 villages at baseline and every year thereafter.

Interventions

  • Behavioral: Dietary sodium reduction
    • Ongoing dietary advice and a supply of a reduced-sodium added-potassium salt substitute

Arms, Groups and Cohorts

  • No Intervention: Control
    • Dietary advice at baseline only
  • Experimental: Dietary sodium reduction
    • Dietary advice and reduced-sodium added-potassium salt substitute

Clinical Trial Outcome Measures

Primary Measures

  • Stroke
    • Time Frame: 5 years
    • The primary outcome will be stroke defined according to standard criteria on the basis of an acute disturbance of focal neurological function and resulting in death or symptoms lasting more than 24 hours. Imaging, clinical and laboratory data will be collected wherever possible.

Secondary Measures

  • Total major vascular events
    • Time Frame: 5 years
    • The composite of stroke, acute coronary syndrome or vascular death
  • Total mortality
    • Time Frame: 5 years

Participating in This Clinical Trial

Inclusion Criteria

  • Disease history – Prior stroke and/or – Aged 60 years or over and with uncontrolled high blood pressure (systolic blood pressure >=140 millimeters of mercury (mmHg) at visit if on blood pressure lowering medication; systolic blood pressure>=160 millimeters of mercury (mmHg) if not on blood pressure lowering medication) – Ownership of a phone by the participant or a household member Exclusion Criteria:

  • Participant or family member is using a potassium-sparing diuretic – Participant or family member is using a potassium supplement – Participant or family member has serious renal impairment – Participant or family member has other reason for concern about use of salt substitute – Participant eats most meals outside the home – Participant is not expected to live longer than 6 months from the date of assessment as estimated by the village doctor – Another family member living in the same household has already been included in the study

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The George Institute
  • Collaborator
    • Peking University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bruce C Neal, PhD, Principal Investigator, The George Institute for Global Health, Australia
    • Yangfeng Wu, PhD, Principal Investigator, The George Institute for Global Health at Peking University Health Science Centre
    • Darwin Labarthe, PhD, Principal Investigator, Northwestern University Feinberg School of Medicine
    • Paul Elliott, PhD, Principal Investigator, School of Public Health, Imperial College London
    • Lijing L Yan, PhD, Principal Investigator, The George Institute for Global Health at Peking University Health Science Centre
    • Nicole Y Li, PhD, Principal Investigator, The George Institute for Global Health, Australia

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.